Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...
Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...
The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in ...
The second vaccine, developed by Moderna in partnership with the National ... does not require time-consuming steps, such as growing ingredients in chicken eggs. Pfizer invested $2 billion of ...
The FDA canceled a vaccine advisory committee meeting to discuss influenza virus strains that should be included in shots for ...
The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...
The Department of Health and Human Services is reevaluating a $590 million contract for avian influenza mRNA vaccines that ...
A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological disorder. The phase 3 study is evaluating the candidate, dubbed mRNA-1403 ...
Moderna did not include potential sales for new products, including its next-generation Covid-19 vaccine, in its 2025 estimates. The team was asked whether this was a reflection of any uncertainty ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback